Market News How it works Learn FAQ
| RCT 0.0923 21.29% | NU 12.5021 -17.53% | EWZ 34.02 -20.12% | BBD 2.877 -29.31% | TGL 0.2429 9.66% | AZTR 2.05 186.71% | ITUB 7.68 -20.58% | SRTM 0.2775 -35.51% | NVD 3.995 -4.65% | XP 15.4801 -49.10% | WFF 0.089 11.25% | SHFS 0.091 -31.27% | SPCX 149.37 1.27% | SOXL 92.37 10.54% | PBR 22.715 -13.17% | VALE 11.99 -3.31% | CLRO 4.84 48.92% | INTC 91.75 5.51% | GCDT 0.1443 -18.06% | TSLL 10.885 11.53% | NWGL 0.0872 6.34% | NOK 8.715 7.06% | NVDA 216.1126 2.44% | SOXS 46.95 -10.50% | CRWV 56.22 3.66% | BITO 10.695 -1.25% | RWM 14.475 -0.52% | GPUS 0.1858 10.01% | SGRY 23.185 47.21% | TSLG 5.445 11.81% | ABEV 2.805 -15.00% | JBLU 2.285 -12.95% | IREN 26.025 4.50% | INTR 4.595 -36.09% | RBNE 0.1682 -11.47% | QID 14.1701 -2.61% | AAL 12.1792 0.57% | TQQQ 68.8286 3.83% | SBS 4.6303 -27.65% | SPDN 8.485 -0.64% | TSLA 393.84 5.81% | T 20.6998 -1.10% | LUCD 0.538 30.90% | SID 0.9075 -23.09% | WULF 12.3201 8.83% | XTND 2.2899 29.37% | NFLX 63.005 -4.32% | CIFR 7.885 -0.69% | SQQQ 38.17 -3.81% | RIG 6.555 2.26%
INIncyte Corporation logo

Incyte Corporation (INCY)

NASDAQ Global Select · Currency in USD
$113.30 ▼ -2.42 (-2.09%)
As of Oct 26, 3:12 PM ET. Market open.

Summary

Previous Close
$115.71
Open
$115.71
Day's Range
$112.75 – $115.86
52 Week Range
$84.02 – $132.60
Volume
1,375,006
Avg. Volume
1,707,112
Market Cap
$22.96B
Beta (5Y Monthly)
0.74
PE Ratio (TTM)
13.94
EPS (TTM)
$8.05
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$134.40

Profile: Incyte Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
2,844
CEO
William J. Meury
Website
incyte.com

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$3.64 · Revenue est. $1.47B
DateEst.Actual
Jul 28, 2026$2.15$3.09Beat
Apr 28, 2026$1.34$1.81Beat
Feb 10, 2026$1.90$1.80Miss
Oct 28, 2025$1.66$2.26Beat
Jul 29, 2025$1.39$1.57Beat
Apr 29, 2025$1.01$1.16Beat

Analyst view

Consensus price target
$134.40 ▲ +18.6%
Range $104.00 – $157.00
Rating: Buy
Buy 52% · Hold 45% · Sell 2%

Get free alerts on INCY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.